TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02061059

Intervention type: OTHER
Group type: OTHER
Intervention: block 1
Description: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements

Intervention type: OTHER
Group type: OTHER
Intervention: block 1
Description: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements

Intervention type: OTHER
Group type: OTHER
Intervention: block 2
Description: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements

Intervention type: OTHER
Group type: OTHER
Intervention: block 2
Description: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements

Intervention type: OTHER
Group type: OTHER
Intervention: standard
Description: patient wears shoes produced with standard method

Intervention type: OTHER
Group type: OTHER
Intervention: standard
Description: patient wears shoes produced with standard method

Intervention type: OTHER
Group type: OTHER
Intervention: with measurements
Description: patient wears shoes produced with plantar pressure measurements

Intervention type: OTHER
Group type: OTHER
Intervention: with measurements
Description: patient wears shoes produced with plantar pressure measurements
Study: NCT03559062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to TEZ/IVA FDC
Study: NCT00308789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biphasic Infant flow NCPAP
Description: Biphasic Nasal continuous positive airway pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure
Study: NCT03118518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Pulmonary vein isolation via ablation with cryoballoon catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Antiarrhythmic drug initiation
Study: NCT04181671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Resistance training with venous blood flow restriction
Description: Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Resistance training
Description: Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
Study: NCT02223351

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151

Intervention type: DRUG
Group type: OTHER
Intervention: ritonavir

Intervention type: DRUG
Group type: OTHER
Intervention: ritonavir
Study: NCT03593954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 100 mg of ritonavir tablet orally.
Study: NCT03559062

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo matched to TEZ/IVA FDC

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo matched to IVA
Study: NCT00003471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00457730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are randomized to either Duloxetine or Placebo
Study: NCT02630810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early oral hydration
Description: starting oral hydration 1 hour following Cesarean Section using 100 ml clear water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed oral hydration
Description: starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
Study: NCT06108908

Intervention type: BEHAVIORAL
Intervention: Reminder
Description: 1. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.

Intervention type: BEHAVIORAL
Intervention: Reminder
Description: 1. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.
Study: NCT04260516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Mucolytic and antioxidant drug
Study: NCT03559062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA
Study: NCT01220245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heparin-bonded ePTFE endoluminal fem-pop bypass
Description: Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical femoro-popliteal bypass.
Description: Surgical femoro-popliteal bypass.
Study: NCT04654949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy
Description: The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
Study: NCT00078286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Dosage ranging from 50 mg to 200 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage ranging from 50 mg to 200 mg once a day
Study: NCT01514383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate (Octylseal )
Description: surgical adhesive
Study: NCT05867056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-I109V Single Ascending Dose
Description: Single dose administration of IMC-I109V

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-I109V Multiple Ascending Doses
Description: Multidose administration of IMC-I109V

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBV HCC Module MAD
Description: Multidose administration of IMC-I109V
Study: NCT04210427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill Motility System & PillCam Patency Capsule
Description: Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
Study: NCT03512964

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir 50 MG
Description: Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]
Description: Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
Study: NCT02753517

Intervention type: DEVICE
Group type: OTHER
Intervention: Hepatobiliary scintigraphy
Description: hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
Study: NCT03832218

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Psychiatric assessment
Description: Psychiatric assessment and neuropsychological tests~* Test : Wechsler Intelligence Scale for Children (WISC-V)~* Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~* Global Assessment of Functioning Scale~* Scale : Brief Psychiatric Rating Scale (BPRS)~* Test : Children Depression Inventory (CDI)~* Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~* Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~* Scale : Conners' scale (parents and teachers)
Study: NCT04634474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suction
Description: Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
Study: NCT01896557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
Study: NCT03301155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaferon for children
Description: Tablet for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study: NCT04076462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029 (octreotide subcutaneous depot)
Description: Octreotide subcutaneous depot for monthly injections in acromegaly patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo for CAM2029
Study: NCT04411329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetics, steriod, alpha 2 blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetics, steriod, alpha 2 blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetics, steriod, alpha 2 blockers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalouridinase
Description: hyalouridinase
Study: NCT03916445

Intervention type: OTHER
Intervention: Connor Davidson Resilience Scale (CD-RISC 10)
Description: questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)

Intervention type: OTHER
Intervention: Connor Davidson Resilience Scale (CD-RISC 10)
Description: questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
Study: NCT00538941

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestlé Noir intense 40 grx2
Description: daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nestlé Placebo Chocolate 40 grx2
Description: Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
Study: NCT02493517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel®
Description: Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide Acetate
Description: Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
Study: NCT01046929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: limonene
Description: oral dosing at 2 gram QD
Study: NCT04371523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo-Hydroxychloroquine
Description: Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Matching Placebo
Study: NCT04498364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training
Description: Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics.
Study: NCT01850589

Intervention type: OTHER
Group type: OTHER
Intervention: Aggressive Therapy
Description: Pharmacotherapy adjuncts offered at no cost are as follows:~* Chantix (varenicline) GlaxoSmithKline,~* Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline.

Intervention type: OTHER
Group type: OTHER
Intervention: Aggressive Therapy
Description: Pharmacotherapy adjuncts offered at no cost are as follows:~* Chantix (varenicline) GlaxoSmithKline,~* Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline.
Study: NCT01519089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690, 550
Description: 5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Study: NCT04329377

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: complete blood count and platelet function
Study: NCT00127205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clodronate disodium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate sodium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study: NCT02493062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonohysterogram
Description: The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
Study: NCT01209377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard
Description: EMDR treatment with bilateral stimulation via eye movement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fixed
Description: EMDR treatment with fixed eyes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: no focus
Description: trauma exposure without external focus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing (EMDR)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing (EMDR)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing (EMDR)
Study: NCT04150159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMD Arm
Description: ProLon Fasting Mimicking Diet Plan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FMD Arm
Description: ProLon Fasting Mimicking Diet Plan
Study: NCT00280215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI / Angiotensin converting enzyme inhibitor
Description: Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB /Angiotensin Receptor Blocker
Description: Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo for 24 months
Study: NCT03912662

Intervention type: DEVICE
Group type: OTHER
Intervention: Mesh augmented reinforcement
Description: Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh
Study: NCT03724253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoBOMB1
Description: \[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoBOMB1
Description: \[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
Study: NCT01979406

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVA
Description: Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVA
Description: Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-PA-1
Description: Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-PA-1
Description: Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-PA-1
Description: Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-PA-GPI-1
Description: Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-PA-GPI-1
Description: Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-PA-GPI-1
Description: Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15